Search

Your search keyword '"Du Pasquier, R."' showing total 282 results
Start Over Author "Du Pasquier, R."
282 results on '"Du Pasquier, R."'

3. Long-Term Consequences of COVID-19: A 1-Year Analysis

Author

Bamps, L., Armenti, J.P., Bojan, M., Grandbastien, B., von Garnier, C., Du Pasquier, R., Desgranges, F., Papadimitriou-Olivgeris, M., Alberio, L., Preisig, M., Schwitter, J., Guery, B., and The RegCOVID Study Group

Subjects
SARS-CoV-2, long COVID-19
Abstract

Long-lasting symptoms after SARS-CoV-2 infection have been described many times in the literature and are referred to as Long COVID. In this prospective, longitudinal, monocentric, observational study, we collected the health complaints of 474 patients (252 ambulatory and 222 hospitalized) at Lausanne University Hospital 1 year after COVID-19 diagnosis. Using a self-reported health survey, we explored cardiopulmonary, vascular, neurological, and psychological complaints. Our results show that age, Charlson comorbidity index, and smoking habits were associated with hospital admission. Regarding the vascular system, we found that having had thromboembolism before SARS-CoV-2 infection was significantly associated with a higher risk of recurrence of thromboembolism at 1 year. In the neurologic evaluation, the most frequent symptom was fatigue, which was observed in 87.5% of patients, followed by "feeling slowed down", headache, and smell disturbance in 71.5%, 68.5%, and 60.7% of cases, respectively. Finally, our cohort subjects scored higher overall in the STAI, CESD, Maastricht, and PSQI scores (which measure anxiety, depression, fatigue, and sleep, respectively) than the healthy population. Using cluster analysis, we identified two phenotypes of patients prone to developing Long COVID. At baseline, CCS score, prior chronic disease, stroke, and atrial fibrillation were associated with Long COVID. During COVID infection, mechanical ventilation and five neurological complaints were also associated with Long COVID. In conclusion, this study confirms the wide range of symptoms developed after COVID with the involvement of all the major systems. Early identification of risk factors associated with the development of Long COVID could improve patient follow-up; nevertheless, the low specificity of these factors remains a challenge to building a systematic approach.

Published
2023

4. Neurologie : ce qui a changé en 2022 [Neurology: what's new in 2022]

Author

Bouvy, C., Caranzano, L., Allali, G., Bally, J., Benninger, D., Beuchat, I., Castro Jimenez, M., Di Virgilio, G., Hirt, L., Michel, P., Novy, J., Pot Kreis, C., Rossetti, A., Rouaud, O., Ryvlin, P., Salvioni Chiabotti, P., Sokolov, A., Strambo, D., Théaudin, M., and Du Pasquier, R.

Subjects
Humans, Cohort Studies, Myasthenia Gravis, Cerebrovascular Disorders, Stroke, Thrombectomy, Neurology, Epilepsy, Treatment Outcome
Abstract

The year 2022 was marked by the development of numerous new treatments for refractory myasthenia gravis. The link between epilepsy and cerebrovascular disorder was studied and lamotrigine discovered to be the optimal treatment choice for epilepsy secondary to stroke to prevent mortality on patient of 45 years and older. New randomized study finally demonstrated the utility of thrombectomy in selected patients with basilar artery occlusion. The causal relationship between Epstein-Barr infection and multiple sclerosis has been proved thanks to a large cohort study. A new possibility of subcutaneous continuous levodopa administration gave promising result. Finally, numerous studies confirmed the efficacy and excellent tolerability of anti-CGRP antibodies.

Published
2023

6. Neurologie [Neurology : what's new in 2021]

Author

Vicino, A., Allali, G., Bally, J., Castro Jimenez, M., Chiabotti Salvioni, P., Hirt, L., Hottinger, A., Michel, P., Novy, J., Pot Kreis, C., Rossetti, A., Rouaud, O., Ryvlin, P., Théaudin, M., and Du Pasquier, R.

Subjects
Brain Ischemia, COVID-19, Endovascular Procedures, Epilepsy, Female, Humans, Neurology, Pregnancy, SARS-CoV-2, Stroke/diagnosis, Stroke/therapy
Abstract

In 2021, we assisted to the publication of new diagnostic criteria, classifications, and guidelines (CIDP, brain tumors, auto-immune encephalitis). Several studies helped to define the pharmacological management of focal and generalized epileptic seizures and epilepsy in pregnant women. The availability of biomarkers and the approval of immunotherapies are modifying the landscape of dementia management. Endovascular interventions without previous thrombolysis seems to be effective in anterior circulation acute ischemic stroke (AIS) and severe posterior circulation AIS. Neurologic complications of Sars-CoV-2 infection were further studied, as well as the efficacy of vaccines in immunosuppressed patients. New molecules and techniques show promising results for the treatment of migraine and cluster headache.

Published
2022

7. Advances in Treatment of Progressive Multifocal Leukoencephalopathy

Author

Bernard-Valnet, R., Koralnik, I.J., and Du Pasquier, R.

Subjects
Adoptive Transfer/methods, Humans, Immune Checkpoint Inhibitors/therapeutic use, Leukoencephalopathy, Progressive Multifocal/drug therapy, Leukoencephalopathy, Progressive Multifocal/therapy, Prognosis, Treatment Outcome
Abstract

Progressive multifocal encephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by JC virus (JCV), which occurs in immunocompromised individuals. Management of PML relies on restoration of immunity within the CNS. However, when this restoration cannot be readily achieved, PML has a grim prognosis. Innovative strategies have shown promise in promoting anti-JCV immune responses, and include T-cell adoptive transfer or immune checkpoint inhibitor therapies. Conversely, management of immune reconstitution inflammatory syndrome, particularly in iatrogenic PML, remains a major challenge. In this paper, we review recent development in the treatment of PML. ANN NEUROL 2021;90:865-873.

Published
2021

8. Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis

Author

Maggi P, Kuhle J, Schädelin S, van der Meer F, Weigel M, Galbusera R, Mathias A, Lu PJ, Rahmanzadeh R, Benkert P, La Rosa F, Bach Cuadra M., Bach Cuadra M, Sati P, Théaudin M, Pot C, van Pesch V, Leppert D, Stadelmann C, Kappos L, Du Pasquier R, Reich DS, Absinta M, and Granziera C

Abstract

Objective:To assess whether chronic white matter inflammation in patients with multiple sclerosis (MS) as detected in vivo by paramagnetic rim MRI lesions (PRLs) is associated with higher serum neurofilament light chain (sNfL) levels, a marker of neuroaxonal damage. Methods:In 118 patients with MS with no gadolinium-enhancing lesions or recent relapses, we analyzed 3D-submillimeter phase MRI and sNfL levels. Histopathologic evaluation was performed in 25 MS lesions from 20 additional autopsy MS cases. Results:In univariable analyses, participants with ≥2 PRLs (n = 43) compared to those with ≤1 PRL (n = 75) had higher age-adjusted sNfL percentiles (median, 91 and 68;p< 0.001) and higher Multiple Sclerosis Severity Scale scores (MSSS median, 4.3 and 2.4;p= 0.003). In multivariable analyses, sNfL percentile levels were higher in PRLs ≥2 cases (βadd, 16.3; 95% confidence interval [CI], 4.6-28.0;p< 0.01), whereas disease-modifying treatment (DMT), Expanded Disability Status Scale (EDSS) score, and T2 lesion load did not affect sNfL. In a similar model, sNfL percentile levels were highest in cases with ≥4 PRLs (n = 30; βadd, 30.4; 95% CI, 15.6-45.2;p< 0.01). Subsequent multivariable analysis revealed that PRLs ≥2 cases also had higher MSSS (βadd, 1.1; 95% CI, 0.3-1.9;p< 0.01), whereas MSSS was not affected by DMT or T2 lesion load. On histopathology, both chronic active and smoldering lesions exhibited more severe acute axonal damage at the lesion edge than in the lesion center (edge vs center:p= 0.004 andp= 0.0002, respectively). Conclusion:Chronic white matter inflammation was associated with increased levels of sNfL and disease severity in nonacute MS, suggesting that PRL contribute to clinically relevant, inflammation-driven neurodegeneration.

Published
2021

9. Neurologie [Recent Advances in Neurology]

Author

Anichini, A., Salvioni Chiabotti, P., Bally, J., Castro Jimenez, M., Démonet, J.F., Di Virgilio, G., Hirt, L., Hottinger, A., Kuntzer, T., Michel, P., Novy, J., Pot Kreis, C., Rossetti, A.O., Rouaud, O., Théaudin, M., and Du Pasquier, R.

Subjects
COVID-19, Female, Humans, Neurology, Neuromyelitis Optica/epidemiology, Pandemics, SARS-CoV-2
Abstract

Significant developments were published in 2020 in the field of blood biomarkers in Alzheimer's disease. Several studies helped to define more accurately the management of status epilepticus and of epilepsy in women of childbearing age. The new Swiss guidelines for the pre-hospital management of acute stroke were issued, as are new targets for stroke prevention. Numerous advances concerning the management of NMO-SD (NeuroMyelitis Optica Spectrum Disorder) were published. Different neurological presentations linked to the COVID-19 pandemic were described (central and peripheral). Several studies confirmed the effectiveness of new migraine treatments (including anti-CGRP). New pharmacological therapies are available for Parkinson's disease.

Published
2021

10. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Author

Wiendl, H., Gold, R., Berger, T., Derfuss, T., Linker, R., Mäurer, M., Aktas, O., Baum, K., Berghoff, M., Bittner, S., Chan, A., Czaplinski, A., Deisenhammer, F., Di Pauli, F., Du Pasquier, R., Enzinger, C., Fertl, E., Gass, A., Gehring, K., Gobbi, C., Goebels, N., Guger, M., Haghikia, A., Hartung, H.P., Heidenreich, F., Hoffmann, O., Kallmann, B., Kleinschnitz, C., Klotz, L., Leussink, V.I., Leutmezer, F., Limmroth, V., Lünemann, J.D., Lutterotti, A., Meuth, S.G., Meyding-Lamadé, U., Platten, M., Rieckmann, P., Schmidt, S., Tumani, H., Weber, F., Weber, M.S., Zettl, U.K., Ziemssen, T., Zipp, F., and ‘Multiple Sclerosis Therapy Consensus Group' (MSTCG)

Subjects
disease-modifying therapy, guideline, multiple sclerosis, treatment recommendation
Abstract

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).

Published
2021

11. CSF lactate for accurate diagnosis of community-acquired bacterial meningitis

Author

Giulieri, S., Chapuis-Taillard, C., Jaton, K., Cometta, A., Chuard, C., Hugli, O., Du Pasquier, R., Bille, J., Meylan, P., Manuel, O., Marchetti, O., Giulieri, S., Chapuis-Taillard, C., Jaton, K., Cometta, A., Chuard, C., Hugli, O., Du Pasquier, R., Bille, J., Meylan, P., Manuel, O., and Marchetti, O.

Abstract

CSF lactate measurement is recommended when nosocomial meningitis is suspected, but its value in community-acquired bacterial meningitis is controversial. We evaluated the diagnostic performance of lactate and other CSF parameters in a prospective cohort of adult patients with acute meningitis. Diagnostic accuracy of lactate and other CSF parameters in patients with microbiologically documented episodes was assessed by receiver operating characteristic (ROC) curves. The cut-offs with the best diagnostic performance were determined. Forty-five of 61 patients (74%) had a documented bacterial (n = 18; S. pneumoniae, 11; N. meningitidis, 5; other, 2) or viral (n = 27 enterovirus, 21; VZV, 3; other, 3) etiology. CSF parameters were significantly different in bacterial vs. viral meningitis, respectively (p < 0.001 for all comparisons): white cell count (median 1333 vs. 143/mm3), proteins (median 4115 vs. 829mg/l), CSF/blood glucose ratio (median 0.1 vs. 0.52), lactate (median 13 vs. 2.3mmol/l). ROC curve analysis showed that CSF lactate had the highest accuracy for discriminating bacterial from viral meningitis, with a cutoff set at 3.5mmol/l providing 100% sensitivity, specificity, PPV, NPV, and efficiency. CSF lactate had the best accuracy for discriminating bacterial from viral meningitis and should be included in the initial diagnostic workup of this condition.

Published
2021

13. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0

Author

Ryom, L, Boesecke, C, Bracchi, M, Ambrosioni, J, Pozniak, A, Arribas, J, Behrens, G, Mallon, P, Puoti, M, Rauch, A, Miro, J, Kirk, O, Marzolini, C, Lundgren, J, Battegay, M, d'Arminio Monforte, A, Clumeck, N, Dedes, N, Gatell, J, Horban, A, Katlama, C, Mccormack, S, Molina, J, Mussini, C, Raffi, F, Reiss, P, Stellbrink, H, Bower, M, Cinque, P, Collins, S, Compston, J, De Wit, S, Fabbri, L, Fux, C, Guaraldi, G, Martinez, E, Papapoulos, S, du Pasquier, R, Poulter, N, Williams, I, Winston, A, Berenguer, J, Bhagani, S, Bruno, R, Konov, S, Lacombe, K, Mauss, S, Mendao, L, Peters, L, Rockstroh, J, Fatkenheuer, G, Furrer, H, Mocroft, A, Morlat, P, Volny-Anne, A, Ryom L., Boesecke C., Bracchi M., Ambrosioni J., Pozniak A., Arribas J., Behrens G., Mallon P. G. M., Puoti M., Rauch A., Miro J. M., Kirk O., Marzolini C., Lundgren J. D., Battegay M., d'Arminio Monforte A., Clumeck N., Dedes N., Gatell J. M., Horban A., Katlama C., McCormack S., Molina J. -M., Mussini C., Raffi F., Reiss P., Stellbrink H. -J., Bower M., Cinque P., Collins S., Compston J., De Wit S., Fabbri L. M., Fux C. A., Guaraldi G., Martinez E., Papapoulos S., du Pasquier R., Poulter N., Williams I., Winston A., Berenguer J., Bhagani S., Bruno R., Konov S., Lacombe K., Mauss S., Mendao L., Peters L., Rockstroh J. K., Fatkenheuer G., Furrer H., Mocroft A., Morlat P., Volny-Anne A., Ryom, L, Boesecke, C, Bracchi, M, Ambrosioni, J, Pozniak, A, Arribas, J, Behrens, G, Mallon, P, Puoti, M, Rauch, A, Miro, J, Kirk, O, Marzolini, C, Lundgren, J, Battegay, M, d'Arminio Monforte, A, Clumeck, N, Dedes, N, Gatell, J, Horban, A, Katlama, C, Mccormack, S, Molina, J, Mussini, C, Raffi, F, Reiss, P, Stellbrink, H, Bower, M, Cinque, P, Collins, S, Compston, J, De Wit, S, Fabbri, L, Fux, C, Guaraldi, G, Martinez, E, Papapoulos, S, du Pasquier, R, Poulter, N, Williams, I, Winston, A, Berenguer, J, Bhagani, S, Bruno, R, Konov, S, Lacombe, K, Mauss, S, Mendao, L, Peters, L, Rockstroh, J, Fatkenheuer, G, Furrer, H, Mocroft, A, Morlat, P, Volny-Anne, A, Ryom L., Boesecke C., Bracchi M., Ambrosioni J., Pozniak A., Arribas J., Behrens G., Mallon P. G. M., Puoti M., Rauch A., Miro J. M., Kirk O., Marzolini C., Lundgren J. D., Battegay M., d'Arminio Monforte A., Clumeck N., Dedes N., Gatell J. M., Horban A., Katlama C., McCormack S., Molina J. -M., Mussini C., Raffi F., Reiss P., Stellbrink H. -J., Bower M., Cinque P., Collins S., Compston J., De Wit S., Fabbri L. M., Fux C. A., Guaraldi G., Martinez E., Papapoulos S., du Pasquier R., Poulter N., Williams I., Winston A., Berenguer J., Bhagani S., Bruno R., Konov S., Lacombe K., Mauss S., Mendao L., Peters L., Rockstroh J. K., Fatkenheuer G., Furrer H., Mocroft A., Morlat P., and Volny-Anne A.

Abstract

Background: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. Guideline highlights: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug–drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. Conclusions: Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated

Published
2018

14. The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile

Author

Métral, M, Darling, K E A; https://orcid.org/0000-0003-1449-3873, Locatelli, I, Nadin, I, Santos, G, Brugger, P, Kovari, H, Cusini, A, Gutbrod, K, Tarr, P E, Calmy, A, Lecompte, T D, Assal, F, Monsch, A, Kunze, U, Stoeckle, M, Schwind, M, Schmid, P, Pignatti, R, Di Benedetto, C, Du Pasquier, R, Cavassini, M, NAMACO study group, Swiss HIV Cohort Study, Métral, M, Darling, K E A; https://orcid.org/0000-0003-1449-3873, Locatelli, I, Nadin, I, Santos, G, Brugger, P, Kovari, H, Cusini, A, Gutbrod, K, Tarr, P E, Calmy, A, Lecompte, T D, Assal, F, Monsch, A, Kunze, U, Stoeckle, M, Schwind, M, Schmid, P, Pignatti, R, Di Benedetto, C, Du Pasquier, R, Cavassini, M, NAMACO study group, and Swiss HIV Cohort Study

Abstract

OBJECTIVES The aim of the study was to examine baseline neurocognitive impairment (NCI) prevalence and factors associated with NCI among patients enrolled in the Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study. METHODS The NAMACO study is an ongoing, prospective, longitudinal, multicentre and multilingual (German, French and Italian) study within the Swiss HIV Cohort Study. Between 1 May 2013 and 30 November 2016, 981 patients ≥ 45 years old were enrolled in the study. All underwent standardized neuropsychological (NP) assessment by neuropsychologists. NCI was diagnosed using Frascati criteria and classified as HIV-associated or as related to other factors. Dichotomized analysis (NCI versus no NCI) and continuous analyses (based on NP test z-score means) were performed. RESULTS Most patients (942; 96.2%) had viral loads < 50 HIV-1 RNA copies/mL. NCI was identified in 390 patients (39.8%): 263 patients (26.8%) had HIV-associated NCI [249 patients (25.4%) had asymptomatic neurocognitive impairment (ANI)] and 127 patients (13%) had NCI attributable to other factors, mainly psychiatric disorders. There was good correlation between dichotomized and continuous analyses, with NCI associated with older age, non-Caucasian ethnicity, shorter duration of education, unemployment and longer antiretroviral therapy duration. CONCLUSIONS In this large sample of aging people living with HIV with well-controlled infection in Switzerland, baseline HIV-associated NCI prevalence, as diagnosed after formal NP assessment, was 26.8%, with most cases being ANI. The NAMACO study data will enable longitudinal analyses within this population to examine factors affecting NCI development and course.

Published
2020

15. How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?

Author

Metral, M, Nadin, I, Locatelli, I, Tarr, P E, Calmy, A, Kovari, H, Brugger, P, Cusini, A, Gutbrod, K, Schmid, P, Schwind, M, Kunze, U, Di Benedetto, C, Pignatti, R, Du Pasquier, R, Darling, K E A; https://orcid.org/0000-0003-1449-3873, Cavassini, M, Metral, M, Nadin, I, Locatelli, I, Tarr, P E, Calmy, A, Kovari, H, Brugger, P, Cusini, A, Gutbrod, K, Schmid, P, Schwind, M, Kunze, U, Di Benedetto, C, Pignatti, R, Du Pasquier, R, Darling, K E A; https://orcid.org/0000-0003-1449-3873, and Cavassini, M

Abstract

OBJECTIVES Diagnosing neurocognitive impairment (NCI) in HIV infection requires time-consuming neuropsychological assessment. Screening tools are needed to identify when neuropsychological referral is indicated. We examined the positive and negative predictive values (PPVs and NPVs, respectively) of the three European AIDS Clinical Society (EACS) screening questions in identifying NCI. METHODS The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study recruited patients aged ≥45 years enrolled in the Swiss HIV Cohort Study between 1 May 2013 and 30 November 2016. NAMACO participants (1) answered EACS screening questions, (2) underwent standardized neuropsychological assessment and (3) completed self-report forms [Center for Epidemiologic Studies Depression Scale (CES-D)] rating mood. NCI categories were defined using Frascati criteria. PPVs and NPVs of the EACS screening questions in identifying NCI categories were calculated. RESULTS Of 974 NAMACO participants with complete EACS screening question data, 244 (25.1%) expressed cognitive complaints in answer to at least one EACS screening question, of whom 51.3% had NCI (26.1% HIV-associated and 25.2% related to confounding factors). The PPV and NPV of the EACS screening questions in identifying HIV-associated NCI were 0.35 and 0.7, respectively. Restricting analysis to NCI with functional impairment or related to confounding factors, notably depression, the NPV was 0.90. Expressing cognitive complaints for all three EACS screening questions was significantly associated with depression (P < 0.001). CONCLUSIONS The EACS screening questions had an NPV of 0.7 for excluding patients with HIV-associated NCI as defined by Frascati criteria. The PPV and NPV may improve if NCI diagnoses are based on new criteria.

Published
2020

17. Diagnosis and Management of Neuromyelitis Optica

Author

Sellner, J., primary, Boggild, M., additional, Clanet, M., additional, Hintzen, R. Q., additional, Illes, Z., additional, Montalban, X., additional, Du Pasquier, R. A., additional, Polman, C. H., additional, Soelberg Sørensen, P., additional, and Hemmer, B., additional

Published
2011
Full Text
View/download PDF

21. Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0

Author

Ryom L., Boesecke C., Bracchi M., Ambrosioni J., Pozniak A., Arribas J., Behrens G., Mallon P. G. M., Puoti M., Rauch A., Miro J. M., Kirk O., Marzolini C., Lundgren J. D., Battegay M., d'Arminio Monforte A., Clumeck N., Dedes N., Gatell J. M., Horban A., Katlama C., McCormack S., Molina J. -M., Mussini C., Raffi F., Reiss P., Stellbrink H. -J., Bower M., Cinque P., Collins S., Compston J., De Wit S., Fabbri L. M., Fux C. A., Guaraldi G., Martinez E., Papapoulos S., du Pasquier R., Poulter N., Williams I., Winston A., Berenguer J., Bhagani S., Bruno R., Konov S., Lacombe K., Mauss S., Mendao L., Peters L., Rockstroh J. K., Fatkenheuer G., Furrer H., Mocroft A., Morlat P., Volny-Anne A., Ryom, L, Boesecke, C, Bracchi, M, Ambrosioni, J, Pozniak, A, Arribas, J, Behrens, G, Mallon, P, Puoti, M, Rauch, A, Miro, J, Kirk, O, Marzolini, C, Lundgren, J, Battegay, M, d'Arminio Monforte, A, Clumeck, N, Dedes, N, Gatell, J, Horban, A, Katlama, C, Mccormack, S, Molina, J, Mussini, C, Raffi, F, Reiss, P, Stellbrink, H, Bower, M, Cinque, P, Collins, S, Compston, J, De Wit, S, Fabbri, L, Fux, C, Guaraldi, G, Martinez, E, Papapoulos, S, du Pasquier, R, Poulter, N, Williams, I, Winston, A, Berenguer, J, Bhagani, S, Bruno, R, Konov, S, Lacombe, K, Mauss, S, Mendao, L, Peters, L, Rockstroh, J, Fatkenheuer, G, Furrer, H, Mocroft, A, Morlat, P, Volny-Anne, A, AII - Infectious diseases, APH - Aging & Later Life, Infectious diseases, Global Health, and AII - Amsterdam institute for Infection and Immunity

Subjects
0301 basic medicine, antiretroviral treatment, Male, Sofosbuvir, HIV Infections, chemistry.chemical_compound, 0302 clinical medicine, Pregnancy, Antiretroviral Therapy, Highly Active, HBV, Pharmacology (medical), Drug Interactions, 030212 general & internal medicine, Pregnancy Complications, Infectious, 610 Medicine & health, Coinfection, Health Policy, EACS Governing Board, Pibrentasvir, Europe, Infectious Diseases, coinfections, Anti-Retroviral Agents, Dolutegravir, HCV, Practice Guidelines as Topic, Female, ART, European AIDS Clinical Society (EACS) Guideline, medicine.drug, Adult, Societies, Scientific, medicine.medical_specialty, comorbiditie, comorbidities, European AIDS Clinical Society guidelines, HIV, opportunistic diseases, AIDS-Related Opportunistic Infections, Humans, Voxilaprevir, 030106 microbiology, Tenofovir alafenamide, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Virology, medicine, opportunistic disease, Intensive care medicine, business.industry, 1103 Clinical Sciences, Glecaprevir, medicine.disease, Transplantation, European AIDS Clinical Society guideline, chemistry, business, human activities
Abstract

BACKGROUND The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. GUIDELINE HIGHLIGHTS Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug-drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. CONCLUSIONS Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.

Published
2018

25. Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary

Author

Achtnichts, L, Chan, A, Czaplinski, A, Derfuss, T, Du Pasquier, R, Findling, O, Gobbi, C, Hoepner, R, Kamber, N, Kamm, C P, Kuhle, J, Lalive, P, Lutterotti, A, Martin, R, Müller, S, Papadopoulou, A, Pot, C, Salmen, A, Schippling, S, Zecca, C, Achtnichts, L, Chan, A, Czaplinski, A, Derfuss, T, Du Pasquier, R, Findling, O, Gobbi, C, Hoepner, R, Kamber, N, Kamm, C P, Kuhle, J, Lalive, P, Lutterotti, A, Martin, R, Müller, S, Papadopoulou, A, Pot, C, Salmen, A, Schippling, S, and Zecca, C

Abstract

More than a dozen substances are meanwhile available for the disease-modifying immunotherapy of multiple sclerosis (MS). However, for some substances, there is a clear difference between approval in Switzerland (Swissmedic) and neighboring countries (European Medicines Agency (EMA)). In addition, limitations imposed by the Swiss Federal Office of Public Health in the specialties list (SL) have significant effects on use in daily clinical practice. In the following, we present consensus recommendations, which were reviewed and agreed upon by the Scientific Advisory Board of the Swiss Multiple Sclerosis Society and the Swiss Neurological Society. We explicitly focus on practice-relevant differences in the approval of MS immunotherapies in Switzerland compared with the EMA area and discuss further limitations (SL) and their impact on the use in clinical practice. Immunotherapies with the same approval in Switzerland and the EMA area and symptomatic therapies are not discussed here.

Published
2019

26. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons

Author

Ryom, L, Boesecke, C, Gisler, V, Manzardo, C, Rockstroh, J, Puoti, M, Furrer, H, Miro, J, Gatell, J, Pozniak, A, Behrens, G, Battegay, M, Lundgren, J, Monforte, A, Arribas, J, Clumeck, N, Dedes, N, Geretti, A, Horban, A, Katlama, C, Mccormack, S, Molina, J, Mussini, C, Raffi, F, Reiss, P, Stellbrink, H, Bower, M, Cinque, P, Collins, S, Compston, J, Deray, G, De Wit, S, Fux, C, Guraldi, G, Mallon, P, Martinez, E, Marzolini, C, Papapoulos, S, du Pasquier, R, Poulter, N, Williams, I, Winston, A, Bhagani, S, Bruno, R, Konov, S, Lacombe, K, Mauss, S, Mendao, L, Peters, L, Rauch, A, Tural, C, Fatkenheuer, G, Kirk, O, Mocroft, A, Morlat, P, Volny-Anne, A, Mulcahy, F, Oprea, C, Youle, M, Ryom L., Boesecke C., Gisler V., Manzardo C., Rockstroh J. K., Puoti M., Furrer H., Miro J. M., Gatell J. M., Pozniak A., Behrens G., Battegay M., Lundgren J. D., Monforte A. D., Arribas J., Clumeck N., Dedes N., Geretti A. M., Horban A., Katlama C., McCormack S., Molina J. M., Mussini C., Raffi F., Reiss P., Stellbrink H. J., Bower M., Cinque P., Collins S., Compston J., Deray G., De Wit S., Fux C. A., Guraldi G., Mallon P., Martinez E., Marzolini C., Papapoulos S., du Pasquier R., Poulter N., Williams I., Winston A., Bhagani S., Bruno R., Konov S., Lacombe K., Mauss S., Mendao L., Peters L., Rauch A., Tural C., Fatkenheuer G., Kirk O., Mocroft A., Morlat P., Volny-Anne A., Mulcahy F., Oprea C., Youle M., Ryom, L, Boesecke, C, Gisler, V, Manzardo, C, Rockstroh, J, Puoti, M, Furrer, H, Miro, J, Gatell, J, Pozniak, A, Behrens, G, Battegay, M, Lundgren, J, Monforte, A, Arribas, J, Clumeck, N, Dedes, N, Geretti, A, Horban, A, Katlama, C, Mccormack, S, Molina, J, Mussini, C, Raffi, F, Reiss, P, Stellbrink, H, Bower, M, Cinque, P, Collins, S, Compston, J, Deray, G, De Wit, S, Fux, C, Guraldi, G, Mallon, P, Martinez, E, Marzolini, C, Papapoulos, S, du Pasquier, R, Poulter, N, Williams, I, Winston, A, Bhagani, S, Bruno, R, Konov, S, Lacombe, K, Mauss, S, Mendao, L, Peters, L, Rauch, A, Tural, C, Fatkenheuer, G, Kirk, O, Mocroft, A, Morlat, P, Volny-Anne, A, Mulcahy, F, Oprea, C, Youle, M, Ryom L., Boesecke C., Gisler V., Manzardo C., Rockstroh J. K., Puoti M., Furrer H., Miro J. M., Gatell J. M., Pozniak A., Behrens G., Battegay M., Lundgren J. D., Monforte A. D., Arribas J., Clumeck N., Dedes N., Geretti A. M., Horban A., Katlama C., McCormack S., Molina J. M., Mussini C., Raffi F., Reiss P., Stellbrink H. J., Bower M., Cinque P., Collins S., Compston J., Deray G., De Wit S., Fux C. A., Guraldi G., Mallon P., Martinez E., Marzolini C., Papapoulos S., du Pasquier R., Poulter N., Williams I., Winston A., Bhagani S., Bruno R., Konov S., Lacombe K., Mauss S., Mendao L., Peters L., Rauch A., Tural C., Fatkenheuer G., Kirk O., Mocroft A., Morlat P., Volny-Anne A., Mulcahy F., Oprea C., and Youle M.

Abstract

Background: The European AIDS Clinical Society (EACS) guidelines are intended for all clinicians involved in the care of HIV-positive persons, and are available in print, online, and as a free App for download for iPhone and Android. Guideline highlights: The 2015 version of the EACS guidelines contains major revisions in all sections; antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Among the key revisions is the recommendation of ART for all HIV-positive persons, irrespectively of CD4 count, based on the Strategic Timing of AntiRetroviral Treatment (START) study results. The recommendations for the preferred and the alternative ART options have also been revised, and a new section on the use of pre-exposure prophylaxis (PrEP) has been added. A number of new antiretroviral drugs/drug combinations have been added to the updated tables on drug-drug interactions, adverse drug effects, dose adjustment for renal/liver insufficiency and for ART administration in persons with swallowing difficulties. The revisions of the coinfection section reflect the major advances in anti-hepatitis C virus (HCV) treatment with direct-acting antivirals with earlier start of treatment in individuals at increased risk of liver disease progression, and a phasing out of interferon-containing treatment regimens. The section on opportunistic diseases has been restructured according to individual pathogens/diseases and a new overview table has been added on CD4 count thresholds for different primary prophylaxes. Conclusions: The diagnosis and management of HIV infection and related coinfections, opportunistic diseases and comorbidities continue to require a multidisciplinary effort for which the 2015 version of the EACS guidelines provides an easily accessable and updated overview.

Published
2016

29. The Combined Quantification and Interpretation of Multiple Quantitative Magnetic Resonance Imaging Metrics Enlightens Longitudinal Changes Compatible with Brain Repair in Relapsing-Remitting Multiple Sclerosis Patients

Author

Bonnier, G., Marechal, B., Fartaria, M.J., Marques, J.P., Simioni, S., Schluep, M., Du Pasquier, R., Thiran, J.-P., Krueger, G., Granziera, C., Bonnier, G., Marechal, B., Fartaria, M.J., Marques, J.P., Simioni, S., Schluep, M., Du Pasquier, R., Thiran, J.-P., Krueger, G., and Granziera, C.

Abstract

Contains fulltext : 181742.pdf (publisher's version ) (Open Access), Objective: Quantitative and semi-quantitative MRI (qMRI) metrics provide complementary specificity and differential sensitivity to pathological brain changes compatible with brain inflammation, degeneration and repair. Moreover, advanced MRI metrics with overlapping elements amplify the true tissue-related information and limit measurement noise. In this work, we combined multiple advanced MRI parameters to assess focal and diffuse brain changes over 2 years in a group of early-stage relapsing-remitting MS patients. Methods: Thirty relapsing-remitting MS patients with less than 5-year disease duration and nine healthy subjects underwent 3T MRI at baseline and after 2 years including T1, T2, T2* relaxometry, and magnetization transfer imaging. To assess longitudinal changes in normal-appearing tissue and lesions, we used analyses of variance and Bonferroni correction for multiple comparisons. Multivariate linear regression was used to assess the correlation between clinical outcome and multiparametric MRI changes in lesions and normal appearing tissue. Results: In patients, we measured a significant longitudinal decrease of mean T2 relaxation times in normal appearing white matter (p = 0.005) and a decrease of T1 relaxation times in the pallidum (p < 0.05), which are compatible with edema reabsorption and/or iron deposition. No longitudinal changes in qMRI metrics were observed in controls. In MS lesions, we measured a decrease in T1 relaxation time (p-value < 2.2e-16) and a significant increase in MTR (p-value < 1e-6), suggesting repair mechanisms such as remyelination, increased axonal density and/or a gliosis. Last, the evolution of advanced MRI metrics - and not changes in lesions or brain volume - were correlated to motor and cognitive tests scores evolution (Adj-R2 > 0.4, p < 0.05). In summary, the combination of multiple advanced MRI provided evidence of changes compatible with focal and diffuse brain repair at early MS stages as suggested by histopathological

Published
2017

32. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons

Author

Ryom, L., Boesecke, C., Gisler, V., Manzardo, C., Rockstroh, J. K., Puoti, M., Furrer, H., Miro, J. M., Gatell, J. M., Pozniak, A., Behrens, G., Battegay, M., Lundgren, J. D., Monforte, A. D., Arribas, J., Clumeck, N., Dedes, N., Geretti, A. M., Horban, A., Katlama, C., Mccormack, S., Molina, J. M., Mussini, C., Raffi, F., Reiss, P., Stellbrink, H. J., Bower, M., Cinque, P., Collins, S., Compston, J., Deray, G., De Wit, S., Fux, C. A., Guraldi, G., Mallon, P., Martinez, E., Marzolini, C., Papapoulos, S., du Pasquier, R., Poulter, N., Williams, I., Winston, A., Bhagani, S., Bruno, R., Konov, S., Lacombe, K., Mauss, S., Mendao, L., Peters, L., Rauch, A., Tural, C., Fatkenheuer, G., Kirk, O., Mocroft, A., Morlat, P., Volny-Anne, A., Mulcahy, F., Oprea, C., Youle, M., Universitat de Barcelona, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Global Health

Subjects
0301 basic medicine, Male, Pathology, medicine.medical_treatment, HIV Infections, Comorbidity, Pre-exposure prophylaxis, 0302 clinical medicine, Immune Reconstitution Inflammatory Syndrome, Pregnancy, Antiretroviral Therapy, Highly Active, Pharmacology (medical), Drug Interactions, 030212 general & internal medicine, Pregnancy Complications, Infectious, 610 Medicine & health, Societies, Medical, Health Policy, Antiretrovirals, Standard of Care, Viral Load, Europe, Infectious Diseases, Coinfection, Female, Post-Exposure Prophylaxis, Adult, medicine.medical_specialty, AIDS-Related Opportunistic Infections, 030106 microbiology, Guidelines as Topic, Antiretroviral treatment, ART, Comorbidities, EACS, Guidelines, HBV, HCV, HIV, Opportunistic infections, CD4 Lymphocyte Count, Humans, Pre-Exposure Prophylaxis, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Immune reconstitution inflammatory syndrome, Comorbiditat, medicine, VIH (Virus), Post-exposure prophylaxis, Intensive care medicine, business.industry, HIV (Viruses), Guideline, medicine.disease, Antiretroviral agents, HIV-positive persons, business, Persones seropositives
Abstract

BACKGROUND The European AIDS Clinical Society (EACS) guidelines are intended for all clinicians involved in the care of HIV-positive persons, and are available in print, online, and as a free App for download for iPhone and Android. GUIDELINE HIGHLIGHTS The 2015 version of the EACS guidelines contains major revisions in all sections; antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Among the key revisions is the recommendation of ART for all HIV-positive persons, irrespectively of CD4 count, based on the Strategic Timing of AntiRetroviral Treatment (START) study results. The recommendations for the preferred and the alternative ART options have also been revised, and a new section on the use of pre-exposure prophylaxis (PrEP) has been added. A number of new antiretroviral drugs/drug combinations have been added to the updated tables on drug-drug interactions, adverse drug effects, dose adjustment for renal/liver insufficiency and for ART administration in persons with swallowing difficulties. The revisions of the coinfection section reflect the major advances in anti-hepatitis C virus (HCV) treatment with direct-acting antivirals with earlier start of treatment in individuals at increased risk of liver disease progression, and a phasing out of interferon-containing treatment regimens. The section on opportunistic diseases has been restructured according to individual pathogens/diseases and a new overview table has been added on CD4 count thresholds for different primary prophylaxes. CONCLUSIONS The diagnosis and management of HIV infection and related coinfections, opportunistic diseases and comorbidities continue to require a multidisciplinary effort for which the 2015 version of the EACS guidelines provides an easily accessable and updated overview.

Published
2015
Full Text
View/download PDF

34. Multiple Sclerosis lesion fingerprint using multicontrast MRI

Author

Bonnier, G., Roche, A., Romascano, D., Simioni, S., Meskaldji, D., Rotzinger, D., Lin, Ying Chia, Gloria Menegaz, Schluep, M., Du Pasquier, R., Johannes, T., Sumpf, Frahm, J., Thiran, J. P. H., Krueger, G., and Granziera, C.

Subjects
Diffusion MRI
Published
2014

35. Cerebellar connectomics provide new biomarkers in early multiple sclerosis

Author

Romascano, D., Meskaldji, D., Bonnier, G., Simioni, S., Rotzinger, D., Lin, Ying Chia, Gloria Menegaz, Roche, A., Schluep, M., Du Pasquier, R., Richiardi, J., Ville, D., Alessandro Daducci, Sumpf T, J., Frahm, J., Thiran, J. P. H., Krueger, G., and Granziera, C.

Subjects
Diffusion MRI
Abstract

The cerebellum is involved in multiple sclerosis (MS), but its implication in early phases is still poorly understood. We investigated structural and functional cerebellar connectivity alterations in early and minimally impaired MS patients, and their correlation to patients’ clinical status. We reconstructed the connectomes of 28 MS patients and 16 healthy controls and performed network statistical analysis. Structural connectivity was found to be altered independently from cerebellar lesion count, volume and disease duration; the microstructural properties of altered connections correlated with patients’ motor and cognitive performance. No topological reorganization or compensatory mechanisms were observed at this stage.

Published
2014

36. PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis

Author

Stravodimou, A., Cairoli, A., Rausch, T., Du Pasquier, R., and Michel, P.

Subjects
surgical procedures, operative, Article Subject, hemic and lymphatic diseases
Abstract

Posttransplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of solid organ transplantation. The majority of PTLD is of B-cell origin, and 90% are associated with the Epstein-Barr virus (EBV). Lymphomatoid granulomatosis (LG) is a rare, EBV-associated systemic angiodestructive lymphoproliferative disorder, which has rarely been described in patients with renal transplantation. We report the case of a patient with renal transplantation for SLE, who presented, 9 months after renal transplantation, an EBV-associated LG limited to the intracranial structures that recovered completely after adjustment of her immunosuppressive treatment. Nine years later, she developed a second PTLD disorder with central nervous system initial manifestation. Workup revealed an EBV-positive PTLD Burkitt lymphoma, widely disseminated in most organs. In summary, the reported patient presented two lymphoproliferative disorders (LG and Burkitt's lymphoma), both with initial neurological manifestation, at 9 years interval. With careful reduction of the immunosuppression after the first manifestation and with the use of chemotherapy combined with radiotherapy after the second manifestation, our patient showed complete disappearance of neurologic symptoms and she is clinically well with good kidney function. No recurrence has been observed by radiological imaging until now.

Published
2012
Full Text
View/download PDF

37. Encephalitis with herpes simplex-2 in the cerebrospinal fluid and anti-RI (ANNA-2) antibodies: an infectious or a paraneoplastic syndrome?

Author

Jan Novy, Eggimann P, Antonio Carota, Andrea O. Rossetti, Pusztaszeri M, and Du Pasquier R

Subjects
Pathology, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Lymphocytic pleocytosis, Neurooncology, Autopsy, General Medicine, Status epilepticus, medicine.disease, Small-cell carcinoma, Article, Cerebrospinal fluid, Biopsy, Immunology, medicine, medicine.symptom, business, Encephalitis
Abstract

We report on a 70-year-old woman with partial complex status epilepticus who was initially diagnosed with herpes simplex-2 (HSV-2) encephalitis, based on brain magnetic resonance imaging (MRI) findings, cerebrospinal fluid (CSF) lymphocytic pleocytosis and HSV-2 DNA detection by polymerase chain reaction (PCR) in the CSF, but without improvement on intravenous acyclovir. Anti-Ri antibodies were positive and computed tomography (CT) investigations revealed a small cell carcinoma at biopsy suggesting paraneoplastic encephalitis. The outcome was unfavourable and the autopsy showed typical features of paraneoplastic encephalitis but no evidence of viral inclusions. This case report is interesting because: (1) it is the first report of an autopsy proven paraneoplastic widespread encephalitis with anti-Ri antibodies; (2) despite a positive HSV-2 PCR in the CSF, there was no sign of herpetic infections of the nervous system; and (3) it illustrates the fact that if paraneoplastic antibodies are usually good markers of the underlying tumour, they are not always predictive of neurological deficits.

Published
2011

38. Health-related quality of life in multiple sclerosis: Effects of natalizumab

Author

Rudick, R. A., Miller, D., Hass, S., Hutchinson, M, Calabresi, P. A., Confavreux, C., Galetta, S. L., Giovannoni, G., Havrdova, E., Kappos, L., Lublin, F. D., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, Ew, Stuart, W. H., Wajgt, A., Weinstock Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., Affirm, Macdonell, SENTINEL Investigators including: R., Hughes, A., Taylor, I., Lee, Y. C., Ma, H., King, J., Kilpatrick, T., Butzkueven, H., Marriott, M., Pollard, J., Spring, P., Spies, J., Barnett, M., Dehaene, I., Vanopdenbosch, L., D’Hooghe, M., Van Zandijcke, M., Derijck, O., Seeldrayers, P., Jacquy, J., Piette, T., De Cock, C., Medaer, R., Soors, P., Vanroose, E., Vanderhoven, L., Nagels, G., Dubois, B., Deville, M. C., D’Haene, R., Jacques, F., Hallé, D., Gagnon, S., Likavcan, E., Murray, T. J., Bhan, V., Mackelvey, R., Maxner, C. E., Christie, S., Giaccone, R., Guzman, D. A., Melanson, M., Esfahani, F., Gomori, A. J., Nagaria, M. H., Grand’Maison, F., Berger, L., Nasreddine, Z., Duplessis, M., Brunet, D., Jackson, A., Pari, G., O’Connor, P., Gray, T., Hohol, M., Marchetti, P., Lee, L., Murray, B., Sahlas, J., Perry, J., Devonshire, V., Hooge, J., Hashimoto, S., Oger, J., Smyth, P., Rice, G., Kremenchutzky, M., Stourac, P., Kadanka, Z., Benesova, Y., Niedermayerova, I., Meluzinova, E., Marusic, P., M, Bojar, Zarubova, K., Houzvicková, E., Piková, J., Talab, R., Faculty, Hospital Olomouc, Olomouc, B. Muchova, Urbánek, K, Kettnerova, Z., Mares, J., Otruba, P., Zapletalová, O., Hradilek, P., Ddolezil, D. Dolezil, Woznicova, I., Höfer, R., Ambler J. Fiedler, Z. Ambler J. Fiedler, Sucha, J., Matousek, V., Rektor, I., Dufek, M., Mikulik, R., Mastik, J., Tyrlikova, I., General, Teaching Hospital, Prague, E. Havrdová, Horakova, D., Kalistová, H., Týblová, M., Ehler, E., Novotná, A., Geier, P., Soelberg Sorensen, P., Ravnborg, M., Petersen, B., Blinkenberg, M., Färkkilä, M., Harno, H., Kallela, M., Häppölä, O., Elovaara, I., Kuusisto, H., Ukkonen, M., Peltola, J., Palmio, J., Pelletier, J., Feuillet, L., Suchet, L., Dalecky, A., Tammam, D., Edan, G., Le Page, E., Mérienne, M., Yaouanq, J., Clanet, M., Mekies, C., Azais Vuillemin, C., Senard, A., Lau, G., Steinmetz, G., Warter V. Wolff, J. Warter V. Wolff, Fleury, M., Tranchant, C., Stark, E., Buckpesch Heberer, U., Henn, K. H., Skoberne, T., Schimrigk, S., Hellwig, K., Brune, N., Weiller, C., Gbadamosi, J., Röther, J., Heesen, C., Buhmann, C., Karageorgiou, C., Korakaki, D., Giannoulis, D. r., Tsiara, S., Thomaides, T., Thomopoulos, I., Papageorgiou, H., Armakola, F., Komoly, S., Rózsa, C., Matolcsi, J., Szabó, G. y., Molnár, B., Lovas, G., Dioszeghy, P., Szulics, P., Magyar, Z., Incze, J., Farkas, J., Clemens, B., Kánya, J., Valicskó, Z. s., Bense, E., Nagy, Z. s., Geréby, G., Perényi, J., Simon, Z. s., Szapper, M., Gedeon, L., Csanyi, A., Rum, G., Lipóth, S., Szegedi, A., Jávor, L., Nagy, I., Adám, I., Szirmai, I., Simó, M., Ertsey, C., I, Amrein, Kamondi, A., Harcos, P., Dobos, E., Szabó, B., Balas, V., Guseo, A., Fodor, E., Jófejü, E., Eizler, K., Csiba, L., Csépány, T., Pallagi, E., Bereczki, D., Jakab, G., Juhász, M., Bszabó, B. Szabó I. Mayer, Katona, G., Hutchinson, M., O’Dwyer, J., O’Rourke, K., Sanders, E. A. C. M., Rijk van Andel, J. F., Bomhof, M. A. M., van Erven, P., Hintzen I. Hoppenbrouwers, R. Q. Hintzen I. Hoppenbrouwers, Neuteboom, R. F., Zemel, D., van Doorn, P. A., Jacobs, B. C., Munster, E. T. h. L. Van, ter Bruggen, J. P., Bernsen, R., Jongen, P. J. H., de Smet, E. A. A., Tacken, H. F. H., Polman, C., Zwemmer, J., Nielsen, J., Kalkers, N., Kragt, J., Jasperse, B., Willoughby, E., Anderson, N. E., Barber, A., Anderson, T., Parkin, P. J., Fink, J., Avery, S., Mason, D., Kwiecinski, H., Zakrzewska Pniewska, B., Kaminska, A., Podlecka, A., Nojszewska, M., Czlonkowska, A., Zaborski, J., Wicha, W., Kruszewska Ozimowska, J., Darda Ledzion, L., Selmaj, K., Mochecka Thoelke, A., Pentela Nowicka, J., Walczak, A., Stasiolek, M., Stelmasiak, Z., Bartosik Psujek, H., Mitosek Szewczyk, K., Belniak, E., Chyrchel, U., Maciejowski, M., Strzyzewska Lubos, L., Lubos, L., Matusik, E., Maciejek, Z., Niezgodzinska Maciejek, A., Sobczynska, D., Slotala, T., Wawrzyniak, S., Kochanowicz K. Kuczynski, J. Kochanowicz K. Kuczynski, Zimnoch, R., Pryszmont, M., Drozdowski, W., Baniukiewicz, E., Kulakowska, A., Borowik, H., Lewonowska, M., Szczudlik, A., Róg, T., Gryz Kurek, E., Pankiewicz, J., Furgal, J., Kimkowicz, A., Fryze, W., Wierbicki, T., Michalak, L., Kowalewska, J., Swiatkiewicz, J., Hillert, J., Åkesson, E, Fredrikson, S., Diener, P, Olsson, T., Wallström, E., Fpiehl, F. Piehl L. Hopia, Brundin, L., Marta, M., Andersson, M., Lycke, J., Runmarker, B., Malmeström, C., Vaghfeldt, P., Skoog, B., Schluep, M., Bogousslavskyr, J., Du Pasquier, R., Achtnichts, L., Kuhle, J., Buitrago Telez, C., Schläger, R., Naegelin, Y., Eraksoy, M., Bebek, N., Akman Demir, G., Topcuoglu, B., Kurtuncu, M., Istanbul, University, Istanbul:, A. Siva, Saip, S., Altintas, A., Kiyat, A., Sharief, M., Kasti, M., Lim, E. T., Rashid, W., Silber, E., Saldanha, G., Hawkins, C., Mamutse, G., Woolmore, J., Hawkes, C., Findley, L., Dasilva, R., Gunasekara, H., Palace, J., Cader, Z., Littleton, E., Burke, G., Sharrack O. Suliman, B. Sharrack O. Suliman, Klaffke, S., Swash, M., Dhillon, H., Bates, D., Westwood, M., Nichol, P., Barnes, D., Wren, D., Stoy, N., Robertson, N., Pickersgill, T., Pearson, O., Lawthom, C., Young, C., Mills, R., Lecky, B., Ford, C., Katzman, J., Rosenberg, G., Cooper, J., Wrubel, B., Richardson, B., Lynch, S., Ridings, L., Mcvey, A., Nowack, W., Rae Grant, A., Mackin, G. A., Castaldo, J. E., Spikol, L. J., Carter, J., Wingerchuk, D., Caselli, R., Dodick, D., Scarberry, S., Bailly, R., Garnaas, K., Haake, B., Rossman, H., Belkin, M., Boudouris, W. D., Pierce, R. P., Mass, M., Yadav, V., Bourdette, D., Whitham, R. H., Heitzman, D., Martin, A., Greenfield, C. F., Agius, M., Richman, D. P., Vijayan, N., Wheelock, V. L., Reder, A., Arnason, B., Noronha, A., Balabanov, R., Ray, A., Sheremata, W., Delgado, S., Shebert, B., Maldonado, J., Bowen, J., Garden, G. A., Distad, B. J., Carrithers, M., Rizzo, M., Vollmer, T., Reiningerova, J., Guarnaccia, J., Lo, A., Richardson, G. B., Fazekas, F., Enzinger, C., Seifert, T., Storch, M., Strasser Fuchs, S., Berger, T., Dilitz, E., Egg, R., Deisenhammer, F., Decoo, : D, Lampaert, J., Bartholome, E., Bier, J., Stenager, : E., Rasmussen, M., Binzer, M., Shorsh, K., Christensen, M., Soelberg Sørensen, P., Hansen, H. J., Bech, E., Petersen, T., Kirkegaard, M., Eralinna, : J., Ruutiainen, J., Soilu Hänninen, M., Säkö, E., Laaksonen, M., Reunanen, M., Remes, A., Keskinarkaus, I., Moreau, : T., Noblet, M., Rouaud, O., Couvreur, G., Lepage, E., Drapier, S., De Burghgraeve, V., Merienne, M., Cahagne, V., Gout, O., Deschamps, R., Le Canuet, P., Moulignier, A., Vermersch, P., De Seze, J., Stojkovic, T., Griffié, G., Engles, Ferriby, D., Debouverie, M., Pittion Vouyouvitch, S., Lacour, J. C., Lubetzki, C., Youssov, K., Mrejen, S., Charles, P., Yaici, S., Clavelou, P., Aufauvre, D., Renouil Guy, N., Cesaro, P., Degos, F., Benisty, S., Rumbach, L., Decavel, P., Blanc, S., Aubertin, P., Riche, G., Brochet, B., Ouallet, J. C., Anne, O., Menck, : S., Grupe, A., Gutmann, E., Lensch, E., Fucik, E., Heitmann, S., Hartung, H. P., Schröter, M., Kurz, F. M. W., Heidenreich, F., Trebst, C., Pul, R., Hohlfeld, R., Krumbholz, M., Pellkofer, H., Haas, J., Segert, A., Meyer, R., Anagnostou, P., Kabus, C., Poehlau, D., Schneider, K., Hoffmann, V., Zettl, U., Steinhagen, V., Adler, S., Steinbrecher E. Rothenfusser Körber, A. Steinbrecher E. Rothenfusser Körber, Zellner, R., Baum, K., Günther, A., Bläsing, H., Stoll, G., Gold, R., Bayas, A., Kleinschnitz, C., Limmroth, V., Katsarava, Z., Kastrup, O., Haller, P., Stoeve, S., Höbel, D., Oschmann, P., Voigt, K., Burger, C. V., Abramsky, : O., Karusiss, D., Achiron, A., Kishner, I., Stern, Y., Sarove Pinhas, I., Dolev, M., Magalashvili, D., Pozzili, : C., Lenzi, D., Scontrini, A., Millefiorini, E., Buttinelli, C., Gallo, P., Ranzato, F., Tiberio, M., Perini, P., Laroni, Alice, Marrosu, M., Cocco P. Marchi, E. Cocco P. Marchi, Spinicci, G., Massole, S., Mascia, M., Floris, G., Trojano, M., Bellacosa, A., Paolicelli, D., Bosco Zimatore, G., Simone, I. L., Giorelli, M., Di Monte, E., Mancardi, GIOVANNI LUIGI, Pizzorno, M., Murialdo, A., Narciso, E., Capello, A., Comi, G., Martinelli, V., Rodegher, M., Esposito, F., Colombo, B., Rossi, P., Polman, : C. H., Jasperse, M. M. S., Zwemmer, J. N. P., Kragt, J. J., De Smet, E., Tacken, H., Frequin, S. T. F. M., Siegers, H. P., Mauser, H. W., Fernandez Fernandez, : O., León, A., Romero, F., Alonso, A., Tamayo, J., Montalban, X., Nos, C., Pelayo, R., Tellez, N., Rio, J., Tintore, M., Arbizu, T., Romero, L., Moral, E., Martinez, S., Kappos, : L., Wilmes, S., Karabudak, : R., Kurne, A., Erdem, S., Siva, A., Atamer, A., Bilgili, F., Topcular, B., Giovannoni, : G., Lava, : N., Murnane, M., Dentinger, M., Zimmerman, E., Reiss, M., Gupta, V., Scott, T., Brillman, J., Kunschner, L., Wright, D., Perel, A., Babu, A., Rivera, V., Killian, J., Hutton, G., Lai, E., Picone, M., Cadivid, D., Kamin, S., Shanawani, M., Gauthier, S., Morgan, A., Buckle, G., Margolin, D., Kwen, P. L., Garg, N., Munschauer, F., Khatri, B., Rassouli, M., Saxena, V., Ahmed, A., Turner, A., Fox, E., Couch, C., Tyler, R., Horvit, A., Fodor, P., Humphries, S., Wynn, D., Nagar, C., O’Brien, D., Allen, N., Turel, A., Friedenberg, S., Carlson, J., Hosey, J., Crayton, H., Richert, J., Tornatore, C., Sirdofsky, M., Greenstein, J., Shpigel, Y., Mandel, S., Adbelhak, T., Schmerler, M., Zadikoff, C., Rorick, M., Reed, R., Elias, S., Feit, H., Angus, E., Sripathi, N., Herbert, J., Kiprovski, K., Qu, X., Del Bene, M., Mattson, D., Hingtgen, C., Fleck, J., Horak, H., Javerbaum, J., Elmore, R., Garcia, E., Tasch, E., Gruener, G., Celesia, G., Chawla, J., Miller, A., Drexler, E., Keilson, M., Wolintz, R., Drasby, E., Muscat, P., Belden, J., Sullivan, R., Cohen, J., Stone, L., Marrie, R. A., Fox, R., Hughes, B., Babikian, P., Jacoby, M., Doro, J., Puricelli, M., Boudoris, W., Pierce, R., Eggenberger, E., Birbeck, G., Martin, J., Kaufman, D., Stuart, W., English, J. B., Stuart, D. S., Gilbert, R. W., Kaufman, M., Putman, S., Diedrich, A., Follmer, R., Pelletier, D., Waubant, E., Cree, B., Genain, C., Goodin, D., Patwa, H., Rizo, M., Kitaj, M., Blevins, J., Smith, T., Mcgee, F., Honeycutt, W., Brown, M., Isa, A., Nieves Quinones, D., Krupp, L., Smiroldo, J., Zarif, M., Perkins, C., Sumner, A., Fisher, A., Gutierrez, A., Jacoby, R., Svoboda, S., Dorn, D., Groeschel, A., Steingo, B., Kishner, R., Cohen, B., Melen, O., Simuni, T., Zee, P., Cohan, S., Yerby, M., Hendin, B., Levine, T., Tamm, H., Travis, L. H., Freedman, S. M., Tim, R., Ferrell, W., Stefoski, D., Stevens, S., Katsamakis, G., Topel, J., Ko, M., Gelber, D., Fortin, C., Green, B., Logan, W., Carpenter, D., Temple, L., Sadiq, S., Sylvester, A., Sim, G., Mihai, C., Vertino, M., Jubelt, B., Mejico, L., Riskind, P., Cabo, A., Paskavitz, J., Moonis, M., Bashir J. Brockington, K. Bashir J. Brockington, Nicholas, A., Slaughter, R., Archer S. Harik, R. Archer S. Harik, Haddad, N., Pippenger, M. A., Van den Noort, S., Thai, G., Olek, M., Demetriou, M., Shin, R., Calabresi, P., Rus, H., Bever, C., Johnson, K., Sherbert, R., Herndon, R., Uschmann, H., Chandler, A., Markowitz, C., Jacobs, D., Balcer, L., Mitchell, G., Chakravorty, S., Heyman, R., Stauber, Z., Goodman, A., Segal, B., Schwid, S., Samkoff, L., Levin, M., Jacewicz, M., Menkes, D., Pulsinelli, W., Frohman, E., Racke, M., Hawker, K., Ulrich, R., Panitch, H., Hamill, R., Tandon, R., Dulaney, E., Simnad, V., Miller, J., Wooten, G. F., Harrison, M., Doherty, M., Wundes, A., Distad, J., Kachuck, N., Berkovich, R., Burnett, M., Sahai, S., Bandari, D., Weiner, L., Storey, J. R., Beesley, B., Hart, D., Moses, H., Sriram, S., Fang, J., O’Duffy, A., Kita, M., Taylor, L., Elliott, M., Roberts, J., Jeffery, D., Maxwell, S., Lefkowitz, D., Kumar, S., Sinclair, M., Radue, E. W., de Vera, A., Bacelar, O., and Kuster, P.

Subjects
Adult, Male, medicine.medical_specialty, Multiple Sclerosis, Visual analogue scale, Health Status, Population, Pain, Comorbidity, Placebo, Antibodies, law.invention, Natalizumab, Randomized controlled trial, Quality of life, Double-Blind Method, law, Internal medicine, Surveys and Questionnaires, Monoclonal, medicine, Prevalence, Humans, Longitudinal Studies, education, Humanized, education.field_of_study, Expanded Disability Status Scale, Neuroscience (all), business.industry, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Female, Patient Satisfaction, Treatment Outcome, United States, Quality of Life, Multiple sclerosis, medicine.disease, Neurology, Physical therapy, Neurology (clinical), business, medicine.drug
Abstract

Objective To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab. Methods HRQoL data were available from 2,113 multiple sclerosis patients in natalizumab clinical studies. In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study, patients received natalizumab 300mg (n = 627) or placebo (n = 315); in the Safety and Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis (SENTINEL) study, patients received interferon beta-1a (IFN-β-1a) plus natalizumab 300mg (n = 589), or IFN-β-1a plus placebo (n = 582). The Short Form-36 (SF-36) and a subject global assessment visual analog scale were administered at baseline and weeks 24, 52, and 104. Prespecified analyses included changes from baseline to week 104 in SF-36 and visual analog scale scores. Odds ratios for clinically meaningful improvement or worsening on the SF-36 Physical Component Summary (PCS) and Mental Component Summary were calculated. Results Mean baseline SF-36 scores were significantly less than the general US population and correlated with Expanded Disability Status Scale scores, sustained disability progression, relapse number, and increased volume of brain magnetic resonance imaging lesions. Natalizumab significantly improved SF-36 PCS and Mental Component Summary scores at week 104 in AFFIRM. PCS changes were significantly improved by week 24 and at all subsequent time points. Natalizumab-treated patients in both studies were more likely to experience clinically important improvement and less likely to experience clinically important deterioration on the SF-36 PCS. The visual analog scale also showed significantly improved HRQoL with natalizumab. Interpretation HRQoL was impaired in relapsing multiple sclerosis patients, correlated with severity of disease as measured by neurological ratings or magnetic resonance imaging, and improved significantly with natalizumab. Ann Neurol 2007

Published
2007

43. EFNS guidelines on diagnosis and management of neuromyelitis optica

Author

Sellner, J, Boggild, M, Clanet, M, Hintzen, R Q, Illes, Z, Montalban, X, Du Pasquier, R A, Polman, C H, Sørensen, Per Soelberg, Hemmer, B, Sellner, J, Boggild, M, Clanet, M, Hintzen, R Q, Illes, Z, Montalban, X, Du Pasquier, R A, Polman, C H, Sørensen, Per Soelberg, and Hemmer, B

Abstract

Neuromyelitis optica (NMO) or Devic's disease is a rare inflammatory and demyelinating autoimmune disorder of the central nervous system (CNS) characterized by recurrent attacks of optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM), which is distinct from multiple sclerosis (MS). The guidelines are designed to provide guidance for best clinical practice based on the current state of clinical and scientific knowledge.

Published
2010

50. Fatal PML associated with efalizumab therapy: Insights into integrin L 2 in JC virus control

Author

Schwab, N., primary, Ulzheimer, J. C., additional, Fox, R. J., additional, Schneider-Hohendorf, T., additional, Kieseier, B. C., additional, Monoranu, C. M., additional, Staugaitis, S. M., additional, Welch, W., additional, Jilek, S., additional, Du Pasquier, R. A., additional, Bruck, W., additional, Toyka, K. V., additional, Ransohoff, R. M., additional, and Wiendl, H., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results